CoChat

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Open access

Published version of a preprint

The DOI matches its Crossref record; 331 of the 348 references it cites were found in a registry or an index; 216 of the 381 sources its claims cite were checked for support.

Abstract

The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.

Overview

CoChat Summary

TL;DR

This 2022 ADA/EASD consensus report updates person-centered management of hyperglycemia in nonpregnant adults with type 2 diabetes, emphasizing holistic care, weight management, physical activity, DSMES, and individualized medication selection. It gives strongest priority to GLP-1 receptor agonists and SGLT2 inhibitors for people with established or high-risk cardiovascular, kidney, or heart failure disease, based on evidence synthesized from trials and meta-analyses published through 13 June 2022.

Key findings

  • A PubMed search identified randomized controlled trials, systematic reviews, and meta-analyses published in English between 28 January 2018 and 13 June 2022; the report built on the 2012, 2015, 2018, and 2019 consensus statements.
  • In a network meta-analysis of 453 trials across nine drug classes, the greatest HbA1c reductions were seen with insulin regimens and GLP-1 RA; subcutaneous semaglutide had the greatest body-weight reduction, and SGLT2i and GLP-1 RA had the greatest blood-pressure reductions.
  • In comparative effectiveness analyses, SGLT2i were superior to GLP-1 RA for reducing heart failure hospitalization and a composite kidney outcome, while GLP-1 RA appeared more efficacious for stroke; no important differences were evident for mortality or other cardiovascular outcomes.
  • The report states that DSMES significantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective; it also reports specific trial effects such as STEP 2 weight loss of 9.6% with semaglutide 2.4 mg, and AWARD-11 and SUSTAIN FORTE showing greater HbA1c and weight reductions with higher-dose GLP-1 RA.

Methods

  • Consensus report written by an ADA/EASD panel, using prior consensus reports as the starting point and incorporating evidence from publications since 2018.
  • Evidence source: PubMed search for English-language RCTs, systematic reviews, and meta-analyses published between 28 January 2018 and 13 June 2022, plus reference-list screening for additional studies.
  • Evidence appraisal: papers were grouped by topic, subgroup meta-analyses were assessed for credibility using relevant guidance, and recommendations were informed by GRADE; draft recommendations were reviewed by invited reviewers and opened for public comment.

Limitations

  • The paper states that subgroup analyses should not be regarded as conclusive and should be formally appraised and ideally complemented by relevant RCTs.
  • The text notes that evidence is limited for some populations because of underrepresentation in trials, including younger people, older adults, women, and non-White participants; this is an evident limitation of generalizability.
  • The report also makes evident that some conclusions rely on network meta-analyses, observational data, and nonrandomized studies, and that some outcomes (e.g., long-term cardiovascular profile of tirzepatide) were still pending, which limits certainty.

Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2337/dci22-0034

Cites

331 of 331 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

140 Valid · 9 Not valid · 61 Not checked · 27 Own results and interpretations

127 more claims · 71 with their cited sources checked

Create a free account to see all 237 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 88
  • Probably not a substantial claim. 21

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

25 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 331 references

Research works printed but not linked: 2

  1. Nathan, Glycemic outcomes in the glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study, N Engl J Med
  2. Nathan, Glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study microvascular and cardiovascular outcomes, N Engl J Med

Cited by

Items 1,501–1,600 of 2,053

Metadata

Authors
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., & Buse, J. B.
Affiliations
  • University of Leicester (GB)
  • Brigham and Women's Hospital (US)
  • National Heart, Lung, and Blood Institute (US)
  • American Diabetes Association (US)
  • Duke University (US)
  • Johns Hopkins University (US)
  • Joslin Diabetes Center (US)
  • 9Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
  • KU Leuven (BE)
  • Università Cattolica del Sacro Cuore (IT)
  • University of Copenhagen (DK)
  • Medical University of Sofia (BG)
  • 17Diabetes Centre, Clinical Research and Evidence-Based Medicine Unit, Aristotle University Thessaloniki, Thessaloniki, Greece
  • University of North Carolina at Chapel Hill (US)
Corresponding author
Buse, John B.
Venue
Diabetes Care
Published
2022-09-28
Volume
45
Issue
11
Pages
2753-2786
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W4296802076
Cited by
2,104
References
348
Citations by year
2026: 500 · 2025: 567 · 2024: 509 · 2023: 396 · 2022: 50
FWCI
282.43
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (submittedVersion, other-oa)
  • Lirias (KU Leuven) (submittedVersion)
Funders
  • European Association for the Study of Diabetes
  • American Diabetes Association
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
type 2 diabetes, hyperglycemia management, glycemic targets, social determinants of health, physical activity, sleep, weight management, SGLT2 inhibitors, GLP-1 receptor agonists, cardiorenal protection, cardiovascular outcomes, renal outcomes
MeSH terms
Glucagon-Like Peptide-1 Receptor, Adult, Diabetes Mellitus, Type 2, Europe, Humans, Hyperglycemia, Hypoglycemic Agents, United States

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.